{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:19:38Z","timestamp":1791091178632,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T00:00:00Z","timestamp":1396915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00280-014-2456-2","type":"journal-article","created":{"date-parts":[[2014,4,7]],"date-time":"2014-04-07T13:16:17Z","timestamp":1396876577000},"page":"1197-1204","source":"Crossref","is-referenced-by-count":77,"title":["Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients"],"prefix":"10.1007","volume":"73","author":[{"given":"Katherine M.","family":"Slusarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa L.","family":"Merker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Muzikansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev A.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,8]]},"reference":[{"key":"2456_CR1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jmg.37.12.897","volume":"37","author":"DG Evans","year":"2000","unstructured":"Evans DG, Sainio M, Baser ME (2000) Neurofibromatosis type 2. J Med Genet 37:897\u2013904","journal-title":"J Med Genet"},{"key":"2456_CR2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG\u00a02nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358\u2013367","journal-title":"N Engl J Med"},{"key":"2456_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","volume":"12","author":"VF Mautner","year":"2010","unstructured":"Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14\u201318","journal-title":"Neuro Oncol"},{"key":"2456_CR4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0022215111002805","volume":"126","author":"GK Eminowicz","year":"2011","unstructured":"Eminowicz GK, Raman R, Conibear J, Plowman PN (2011) Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J Laryngol Otol 126:79\u201382","journal-title":"J Laryngol Otol"},{"key":"2456_CR5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046\u20131052","journal-title":"Otol Neurotol"},{"key":"2456_CR6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","volume":"124","author":"B Nazer","year":"2011","unstructured":"Nazer B, Humphreys BD, Moslehi J (2011) Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 124:1687\u20131691","journal-title":"Circulation"},{"key":"2456_CR7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1634\/theoncologist.2012-0339","volume":"18","author":"HI Hurwitz","year":"2013","unstructured":"Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O (2013) Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 18:273\u2013280","journal-title":"Oncologist"},{"key":"2456_CR8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/annonc\/mds593","volume":"24","author":"SR Shah","year":"2013","unstructured":"Shah SR, Gressett Ussery SM, Dowell JE, Marley E, Liticker J, Arriaga Y, Verma U (2013) Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension. Ann Oncol 24:960\u2013965","journal-title":"Ann Oncol"},{"key":"2456_CR9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","volume":"30","author":"ES Robinson","year":"2010","unstructured":"Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD (2010) Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 30:591\u2013601","journal-title":"Semin Nephrol"},{"key":"2456_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-113-1-39","volume":"113","author":"JJ Mulvihill","year":"1990","unstructured":"Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R (1990) NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113:39\u201352","journal-title":"Ann Intern Med"},{"key":"2456_CR11","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1212\/01.WNL.0000035638.74084.F4","volume":"59","author":"ME Baser","year":"2002","unstructured":"Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG (2002) Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:1759\u20131765","journal-title":"Neurology"},{"key":"2456_CR12","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560\u20132572","journal-title":"JAMA"},{"key":"2456_CR13","doi-asserted-by":"crossref","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, Lefevre ML, Mackenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2013) 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA","DOI":"10.1001\/jama.2013.284427"},{"key":"2456_CR14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","volume":"102","author":"ML Maitland","year":"2010","unstructured":"Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596\u2013604","journal-title":"J Natl Cancer Inst"},{"key":"2456_CR15","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1002\/cncr.28343","volume":"119","author":"J Fangusaro","year":"2013","unstructured":"Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Kun LE, Fouladi M (2013) Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a pediatric brain tumor consortium study (PBTC-022). Cancer 119:4180\u20134187","journal-title":"Cancer"},{"key":"2456_CR16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajh.2010.25","volume":"23","author":"V Ranpura","year":"2010","unstructured":"Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23:460\u2013468","journal-title":"Am J Hypertens"},{"key":"2456_CR17","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ajmg.a.34035","volume":"155A","author":"RE Hornigold","year":"2011","unstructured":"Hornigold RE, Golding JF, Ferner RE, Ferner RE (2011) Neurofibromatosis 2: a novel risk factor for hypertension? Am J Med Genet A 155A:1721\u20131722","journal-title":"Am J Med Genet A"},{"key":"2456_CR18","unstructured":"Miller K, Rugo HS, Cobleigh MA (2002) Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 76:S37"},{"key":"2456_CR19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427\u2013434","journal-title":"N Engl J Med"},{"key":"2456_CR20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","volume":"20","author":"M Scartozzi","year":"2009","unstructured":"Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20:227\u2013230","journal-title":"Ann Oncol"},{"key":"2456_CR21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/bjc.2011.2","volume":"104","author":"P Osterlund","year":"2011","unstructured":"Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P (2011) Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 104:599\u2013604","journal-title":"Br J Cancer"},{"key":"2456_CR22","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00280-011-1604-1","volume":"68","author":"SA De","year":"2011","unstructured":"De SA, Carlomagno C, Pepe S, Bianco R, De PS (2011) Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 68:1207\u20131213","journal-title":"Cancer Chemother Pharmacol"},{"key":"2456_CR23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdn729","volume":"20","author":"P Bono","year":"2009","unstructured":"Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, Joensuu H (2009) Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 20:393\u2013394","journal-title":"Ann Oncol"},{"key":"2456_CR24","unstructured":"Harzstark AL, Halabi S, Stadler WM et al (2013) Hypertension is associated with clinical outcome for patients (pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206. Genitourinary Cancers Symposium"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2456-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2456-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T08:55:52Z","timestamp":1565340952000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2456-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,8]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2456"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2456-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,8]]}}}